Generate Biomedicines, a Phase 3 biotech using an AI drug discovery platform to develop severe asthma therapies, announced terms for its IPO on Monday.
The Somerville, MA-based company plans to raise $400 million by offering 25 million shares at a price range of $15 to $17.
Generate Biomedicines states that its AI-enabled Generate Platform is a tight and fully-integrated loop (design–build–test–learn) aimed to create proprietary, therapeutically relevant data and differentiated molecular solutions. The company claims that its therapeutic potential has been demonstrated by successfully progressing three computationally engineered proteins into human clinical testing, the most advanced of which is GB-0895, an investigational long-acting anti-thymic stromal lymphopoietin (“TSLP”) monoclonal antibody, which is enrolling patients in pivotal Phase 3 clinical trials for severe asthma.
Generate Biomedicines was founded in 2018 and booked $32 million in revenue for the 12 months ended December 31, 2025. It plans to list on the Nasdaq under the symbol GENB. Goldman Sachs, Morgan Stanley, Piper Sandler, Guggenheim Securities, and Cantor Fitzgerald are the joint bookrunners on the deal. It is expected to price the week of February 23rd, 2026.
